James R Berenson, MD, Inc.
West Hollywood, CA
Accepting patients
Selinexor for Lenalidomide-Refractory Patients
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
- SINE
- Phase 1
Accepting patients
Selinexor
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- SINE
- Randomization
- Phase 3
Accepting patients
Ruxolitinib
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- Kinase Inhibitor
- Phase 1
- Has results
Accepting patients
SubQSA
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
Venetoclax Plus Isatuximab and Dexamethasone
A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)
- Phase 2
Accepting patients
KPT-IST-391
A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma
- Exportin-1 (XPO1) Inhibitor
- SINE
- Phase 1
Accepting patients
Ruxolitinib Combination Therapy
Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in Serum B-Cell Maturation Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Disease Progression in Order to Add Lenalidomide to Those Failing the Ruxolitinib/Methylprednisolone Combination
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 1